We always look beyond the products we make in order to find better solutions for treating some of the world’s toughest diseases. At AbbVie, we focus on developing medicines that deliver strong clinical performance, provide significant benefits for patients and deliver economic value, particularly where there is significant need. Our expertise in both small molecules and biologics gives us the flexibility to find and pursue the best solution for patients.
AbbVie recognises the strength and capability of local medical researchers and selected Australia as one of only ten countries for global Phase II and III clinical trials of its industry-leading bio-pharmaceuticals pipeline; a testament to the world-leading medical institutions here in Australia.
We are currently testing 17 compounds in around 85 studies, with more than 1000 patients enrolled at 300 sites across Australia.
We understand that progress often comes more quickly working together than alone. That’s why we collaborate with external researchers, other companies, medical societies, patient advocates and many other stakeholders to gain a better understanding of how we can make the most significant contributions.